Showing results (91-100 of 418) with videos related to
Sort By:
Pageof 42
Trends in Cancer|December 10, 2021
Impact of tissue-agnostic approvals for patients with sarcomaRoberto Carmagnani Pestana, Juliana Rodrigues Beal, Amanda Parkes, et al.Cell|January 18, 2020
The Master Observational Trial: A New Class of Master Protocol to Advance Precision MedicineDane Dickson, Jennifer Johnson, Raymond Bergan, et al.British Journal of Cancer|March 14, 2023
The emerging role of PI3K inhibitors for solid tumour treatment and beyondCarmen Belli, Matteo Repetto, Santosh Anand, et al.Cancer Medicine|January 23, 2021
Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastasesJustin T Moyers, Esther G Chong, Jiahao Peng, et al.Cancers|November 27, 2024
Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?Aakash Desai, Vivek Subbiah, Sinchita Roy-Chowdhuri, et al.Abdominal Radiology (New York)|January 2, 2021
Current update on gallbladder carcinomaDhakshinamoorthy Ganeshan, Avinash Kambadakone, Paul Nikolaidis, et al.Cancer Treatment and Research Communications|September 30, 2025
Development of anti-cancer medicines in the current eraBradley J Monk, Manish R Patel, Sarper Toker, et al.Trends in Cancer|August 15, 2021
Precision therapy for RET-altered cancers with RET inhibitorsKyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, et al.BMC Medicine|September 15, 2021
The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapySreeram Ramagopalan, Thomas P Leahy, Joshua Ray, et al.Journal of the National Cancer Institute|November 9, 2017
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma TumorsShiraj Sen, Funda Meric-Bernstam, David S Hong, et al.Pageof 42